Therapeutic Area

Drug/ Target

Indication
Preclinical
Phase 1
Phase 2
Phase 3
NDA Filing

Anticipated Milestones

Anticipated Milestones
FDA and EMA submissions in 2020
Topline data expected in 2020
Topline data expected in Q3 2020
Anticipated Milestones

LUMINA-1 topline data expected in Q2 and LUMINA-2 later in 2020

Vifor has future option

Drug: Indication (Target)
Pre
PI
PII
PIII
NDA
Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

Progress in TH17 Disease

CCX559 / PD-1 / PD-L1

Anticipated Milestones

Advance CCX872 in combination with other therapies

Oral Administered Small Molecule Checkpoint Inhibitors